These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23207797)

  • 1. Potential biomarker for aspirin use in colorectal cancer therapy.
    Langley RE; Rothwell PM
    Nat Rev Clin Oncol; 2013 Jan; 10(1):8-10. PubMed ID: 23207797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies.
    Paleari L; Puntoni M; Clavarezza M; DeCensi M; Cuzick J; DeCensi A
    Clin Oncol (R Coll Radiol); 2016 May; 28(5):317-26. PubMed ID: 26712086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.
    Liao X; Lochhead P; Nishihara R; Morikawa T; Kuchiba A; Yamauchi M; Imamura Y; Qian ZR; Baba Y; Shima K; Sun R; Nosho K; Meyerhardt JA; Giovannucci E; Fuchs CS; Chan AT; Ogino S
    N Engl J Med; 2012 Oct; 367(17):1596-606. PubMed ID: 23094721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.
    Domingo E; Church DN; Sieber O; Ramamoorthy R; Yanagisawa Y; Johnstone E; Davidson B; Kerr DJ; Tomlinson IP; Midgley R
    J Clin Oncol; 2013 Dec; 31(34):4297-305. PubMed ID: 24062397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspirin therapy for colorectal cancer with PIK3CA mutation: simply complex!
    Fuchs CS; Ogino S
    J Clin Oncol; 2013 Dec; 31(34):4358-61. PubMed ID: 24166520
    [No Abstract]   [Full Text] [Related]  

  • 6. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
    Ogino S; Lochhead P; Giovannucci E; Meyerhardt JA; Fuchs CS; Chan AT
    Oncogene; 2014 Jun; 33(23):2949-55. PubMed ID: 23792451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Aspirin and PIK3CA mutation in colorectal cancer].
    Kirstein MM; Vogel A
    Z Gastroenterol; 2014 Mar; 52(3):306-7. PubMed ID: 24622874
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation.
    Kothari N; Kim R; Jorissen RN; Desai J; Tie J; Wong HL; Faragher I; Jones I; Day FL; Li S; Sakthinandeswaren A; Palmieri M; Lipton L; Schell M; Teer JK; Shibata D; Yeatman T; Sieber OM; Gibbs P; Tran B
    Acta Oncol; 2015 Apr; 54(4):487-92. PubMed ID: 25549537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis.
    Li P; Wu H; Zhang H; Shi Y; Xu J; Ye Y; Xia D; Yang J; Cai J; Wu Y
    Gut; 2015 Sep; 64(9):1419-25. PubMed ID: 25239119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin, PIK3CA mutation, and colorectal-cancer survival.
    Sahin IH; Garrett C
    N Engl J Med; 2013 Jan; 368(3):289. PubMed ID: 23323915
    [No Abstract]   [Full Text] [Related]  

  • 11. Aspirin, PIK3CA mutation, and colorectal-cancer survival.
    Viúdez A; Hernandez I; Vera R
    N Engl J Med; 2013 Jan; 368(3):289. PubMed ID: 23323914
    [No Abstract]   [Full Text] [Related]  

  • 12. Aspirin, PIK3CA mutation, and colorectal-cancer survival.
    Ogino S; Liao X; Chan AT
    N Engl J Med; 2013 Jan; 368(3):289-90. PubMed ID: 23323913
    [No Abstract]   [Full Text] [Related]  

  • 13. Aspirin extends life of some patients with colorectal cancer.
    Printz C
    Cancer; 2013 Feb; 119(3):472-3. PubMed ID: 23341305
    [No Abstract]   [Full Text] [Related]  

  • 14. Aspirin Treatment Effect and Association with PIK3CA Mutation in Breast Cancer: A Biomarker Analysis.
    Zhou Y; Simmons J; Jordan CD; Sonbol MB; Maihle N; Tang SC
    Clin Breast Cancer; 2019 Oct; 19(5):354-362.e7. PubMed ID: 31262687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis.
    Wu S; Gan Y; Wang X; Liu J; Li M; Tang Y
    J Cancer Res Clin Oncol; 2013 May; 139(5):891-900. PubMed ID: 23435830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer.
    Reimers MS; Bastiaannet E; Langley RE; van Eijk R; van Vlierberghe RL; Lemmens VE; van Herk-Sukel MP; van Wezel T; Fodde R; Kuppen PJ; Morreau H; van de Velde CJ; Liefers GJ
    JAMA Intern Med; 2014 May; 174(5):732-9. PubMed ID: 24687028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in PIK3CA Sensitize Breast Cancer Cells to Physiologic Levels of Aspirin.
    Dirican E
    Asian Pac J Cancer Prev; 2016; 17(5):2731. PubMed ID: 27268661
    [No Abstract]   [Full Text] [Related]  

  • 18. Aspirin--from prevention to targeted therapy.
    Pasche B
    N Engl J Med; 2012 Oct; 367(17):1650-1. PubMed ID: 23094728
    [No Abstract]   [Full Text] [Related]  

  • 19. [Aspirin and colorectal cancer].
    Grancher A; Michel P; Di Fiore F; Sefrioui D
    Bull Cancer; 2018 Feb; 105(2):171-180. PubMed ID: 29153543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
    De Roock W; Claes B; Bernasconi D; De Schutter J; Biesmans B; Fountzilas G; Kalogeras KT; Kotoula V; Papamichael D; Laurent-Puig P; Penault-Llorca F; Rougier P; Vincenzi B; Santini D; Tonini G; Cappuzzo F; Frattini M; Molinari F; Saletti P; De Dosso S; Martini M; Bardelli A; Siena S; Sartore-Bianchi A; Tabernero J; Macarulla T; Di Fiore F; Gangloff AO; Ciardiello F; Pfeiffer P; Qvortrup C; Hansen TP; Van Cutsem E; Piessevaux H; Lambrechts D; Delorenzi M; Tejpar S
    Lancet Oncol; 2010 Aug; 11(8):753-62. PubMed ID: 20619739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.